Clearside Biomedical (CLSD) to Release Earnings on Thursday

Clearside Biomedical (NASDAQ:CLSD) will be releasing its earnings data after the market closes on Thursday, May 9th. Analysts expect Clearside Biomedical to post earnings of ($0.14) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The firm had revenue of $6.35 million for the quarter, compared to analysts’ expectations of $3.40 million. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Price Performance

NASDAQ:CLSD opened at $1.26 on Tuesday. Clearside Biomedical has a 12 month low of $0.65 and a 12 month high of $2.12. The business’s fifty day moving average price is $1.45 and its 200 day moving average price is $1.25.

Wall Street Analysts Forecast Growth

CLSD has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a report on Thursday, March 14th. Needham & Company LLC reissued a “buy” rating and set a $4.00 price objective on shares of Clearside Biomedical in a report on Thursday, April 11th. Wedbush reaffirmed an “outperform” rating and issued a $4.00 target price (down from $5.00) on shares of Clearside Biomedical in a research report on Wednesday, March 13th. StockNews.com raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Clearside Biomedical in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Clearside Biomedical has a consensus rating of “Moderate Buy” and a consensus price target of $4.75.

Insider Activity at Clearside Biomedical

In other Clearside Biomedical news, insider Ngai Hang Victor Chong acquired 30,000 shares of the stock in a transaction on Wednesday, March 20th. The shares were bought at an average cost of $1.60 per share, with a total value of $48,000.00. Following the transaction, the insider now owns 30,000 shares of the company’s stock, valued at approximately $48,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Ngai Hang Victor Chong acquired 30,000 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was bought at an average cost of $1.60 per share, with a total value of $48,000.00. Following the transaction, the insider now owns 30,000 shares of the company’s stock, valued at $48,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bradford T. Whitmore bought 444,444 shares of the stock in a transaction on Wednesday, February 7th. The stock was bought at an average price of $1.35 per share, for a total transaction of $599,999.40. Following the completion of the purchase, the insider now directly owns 4,495,034 shares in the company, valued at approximately $6,068,295.90. The disclosure for this purchase can be found here. Insiders acquired a total of 481,154 shares of company stock worth $656,387 in the last 90 days. 9.80% of the stock is owned by insiders.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.